Tagged with Artificial Intelligence

UAE As Abu Dhabi translates strategy into execution, the focus turns from platform design to operational delivery. Albarah Elkhani, COO of Integrated Health Solutions at M42, details how large-scale genomics, clinical pathways and regulatory alignment are embedded into day-to-day healthcare practice. From premarital and newborn screening to rare disease management and…

UAE Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an integrated platform spanning care delivery, genomics, digital infrastructure and policy seeks to realign incentives, embed intelligence at scale and reposition…

Taiwan Professor Yun-Ching Fu serves as Superintendent of Taichung Veterans General Hospital, Taiwan’s largest national medical centre in the central region. A paediatric interventional cardiologist by training, Professor Fu established Taiwan records for minimally invasive cardiac defect repair and now leads a 1,632-bed institution serving 10,000 outpatients daily. Under his leadership,…

Taiwan Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps Research and his tenure as President of Academia Sinica. With a unique vantage point spanning both American and Taiwanese scientific…

Global ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and outcomes research (HEOR) and healthcare decision-making. Abbott highlights concrete use cases in genomics, evidence synthesis, and medical imaging, while stressing…

LatAm Latin America faces one of the most complex healthcare landscapes in the world, where fast-growing demand collides with deep structural inequities and limited resources. In this interview, Fabrizio Signorin, President Latin America at Siemens Healthineers, shares how the organisation is working with governments and providers to reimagine care delivery, expand…

Taiwan PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren Wang outlines how ONIVYDE® provides the stability to advance a more ambitious pipeline, how a virtual model sharpens scientific focus…

France Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health institutions. Drawing on extensive oncology expertise and a deep commitment to national competitiveness, he champions a unique model in which…

Global First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible efficacy trials when patient numbers make traditional statistics unworkable. She charts how AI, Bayesian methods, transfer learning, and synthetic data…

France Created in the wake of COVID-19, the Agence de l’Innovation en Santé (AIS), part of the Secrétariat Général pour l’investissement – a Prime Minister department, has rapidly positioned itself at the heart of France’s health innovation strategy, driving progress in areas such as bioclusters, prevention, clinical research, and artificial intelligence.…

Global As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the UK and drawing on over 25 years of clinical development leadership across Lilly, Pfizer, Takeda, and Moderna, Dr Ivarsson recently…

Switzerland QIAGEN’s Sample Technologies portfolio sits at the core of the company’s mission to deliver the highest-quality products to enable valuable molecular insights to more than 500,000 customers across life sciences and clinical diagnostics. Under the leadership of Michael Scheffler, Vice President and Head of Global Sample Technologies, this portfolio continues…